Hyperbaric oxygen therapy: no change detected in certain biomarkers in 17 men

Hyperbaric oxygen therapy may affect biological pathways linked to inflammation, but that does not guarantee an effect on every marker. In an exploratory analysis involving 17 healthy, physically active men, ten sessions produced no statistically significant difference in the biomarkers studied compared with the control group. However, this small sample cannot rule out more modest effects.

Hyperbaric oxygen therapy chamber used to administer oxygen under pressure.
Gadgets & TechEditorial illustration, not study data.

A biomarker analysis drawn from a randomized trial

The researchers studied anandamide, or AEA, a molecule in the endocannabinoid system, and lipopolysaccharide, or LPS, as primary outcomes. Cannabinoid receptor type 2, CB2R, and the enzyme FAAH were included in secondary or exploratory analyses.

The subsample included nine men who received hyperbaric oxygen therapy and eight controls. Treatment consisted of ten sessions, six per week, with exposure to pure oxygen at a pressure of 2.5 atmospheres absolute. Fasting blood samples were collected before and after the program.

The original trial was randomized, but this analysis relies on a selection made after randomization. Treated participants came from a subgroup scheduled for morning sessions. Controls were selected before the assays to improve comparability in baseline body mass index. This selection limits the strength of the comparison.

No significant difference in the markers measured

Changes in AEA, LPS, CB2R and FAAH did not differ significantly between groups. The researchers also observed no significant change within the treated group.

This result does not demonstrate that hyperbaric oxygen therapy has no biological effects whatsoever. It indicates that this analysis detected no change in these circulating markers under the conditions studied. The available abstract does not report the magnitudes of the differences or their confidence intervals, limiting assessment of their importance.

A baseline association that proves no mechanism

Before treatment, AEA and LPS concentrations were positively associated. This exploratory observation cannot establish whether one influences the other, nor can it support an inference about a treatment effect. The authors state that it needs to be confirmed in adequately powered studies.

Assessing the value of hyperbaric oxygen therapy also requires distinguishing a blood test result from a tangible benefit. This analysis demonstrates no improvement in symptoms, recovery or long-term health. Its findings also do not support conclusions about women, people with illnesses or other treatment programs.

Limitations to keep in mind

Only the PubMed abstract was consulted, not the full text. The sample is small, exclusively male, and the subsample was selected after randomization. Effect sizes and their confidence intervals are not provided in the abstract. Adverse effects, funding and conflicts of interest could not be verified.

What we can take away

These data do not support the idea that ten sessions of hyperbaric oxygen therapy alter the endocannabinoid markers and LPS measured in these active men. They remain too limited to rule out a modest effect or assess clinical benefit.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.